BR112012025567A2 - peptídeos de cdca5 e vacinas que incluem os mesmos - Google Patents

peptídeos de cdca5 e vacinas que incluem os mesmos

Info

Publication number
BR112012025567A2
BR112012025567A2 BR112012025567A BR112012025567A BR112012025567A2 BR 112012025567 A2 BR112012025567 A2 BR 112012025567A2 BR 112012025567 A BR112012025567 A BR 112012025567A BR 112012025567 A BR112012025567 A BR 112012025567A BR 112012025567 A2 BR112012025567 A2 BR 112012025567A2
Authority
BR
Brazil
Prior art keywords
cancer
peptides
nucleic acids
vaccines
mentioned
Prior art date
Application number
BR112012025567A
Other languages
English (en)
Inventor
Ohsawa Ryuji
Yoshimura Sachiko
Tsunoda Takuya
Watanabe Tomoshisa
Nakamura Yusuke
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of BR112012025567A2 publication Critical patent/BR112012025567A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

peptídeos de cdca5 e vacinas que incluem os mesmos a presente invenção refere-se a peptídeos isolados derivados de seq id no: 21 e fragmentos dos mesmos que se ligam a um antígeno hla e induzem a linfócitos t citotóxicos (cytotoxic t lymphocytes - ctl ) e , assim, são adequados para uso no contexto de imunoterapia de câncer, mais particularmente vacinas de câncer , são descritos aqui. os peptídeos da invenção abrangem as sequências de aminoácidos mencionados acima e versões modificadas das mesmas nas quais um , dois ou vários aminoácidos são substituídos , deletados, inseridos ou adicionados, contanto que tais versões modificados retenham a lilgação ao hla e/ou indutibilidade de cti das sequências originais . ainda proporcionados são ácidos nucleicos que codificam qualquer um dos peptídeos mencionados acima , bem como agentes , substâncias e/ou composições farmacêuticas que incluem ou incorporam qualquer um dos peptídeos ou ácidos nucleicos antes mencionados. os peptídeos, ácidos nucleicos , agentes farmacêuticos, substâncias e composições da presente invenção encontram utilidade particular no tratamento de cânceres e tumores incluinodo, por exemplo, aml, câncer de bexiga, câncer de mama, câncer cervical, carcinoma colangiocelular, cml, câncer cólon-retal câncer de esôfago, câncer gástrico, câncer gástrico do tipo difuso, cânccer de pulmão, linfoma, câncer de próstata, sclc e tumor de tecidos moles
BR112012025567A 2010-04-09 2011-04-07 peptídeos de cdca5 e vacinas que incluem os mesmos BR112012025567A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32267610P 2010-04-09 2010-04-09
PCT/JP2011/002078 WO2011125334A1 (en) 2010-04-09 2011-04-07 Cdca5 peptides and vaccines including the same

Publications (1)

Publication Number Publication Date
BR112012025567A2 true BR112012025567A2 (pt) 2019-09-24

Family

ID=44762304

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012025567A BR112012025567A2 (pt) 2010-04-09 2011-04-07 peptídeos de cdca5 e vacinas que incluem os mesmos

Country Status (14)

Country Link
US (1) US20130108664A1 (pt)
EP (1) EP2556084A4 (pt)
JP (1) JP2013523084A (pt)
KR (1) KR20130043627A (pt)
CN (1) CN102947325B (pt)
AU (1) AU2011236397A1 (pt)
BR (1) BR112012025567A2 (pt)
CA (1) CA2795534A1 (pt)
MX (1) MX2012011668A (pt)
RU (1) RU2012147590A (pt)
SG (2) SG10201502791YA (pt)
TW (1) TW201138806A (pt)
WO (1) WO2011125334A1 (pt)
ZA (1) ZA201207416B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150091311A (ko) * 2012-12-04 2015-08-10 온코세라피 사이언스 가부시키가이샤 Sema5b 펩타이드 및 이를 포함하는 백신
WO2014106886A1 (en) * 2013-01-07 2014-07-10 Oncotherapy Science, Inc. Cdca5 peptides and vaccines containing the same
TW201636358A (zh) * 2014-12-09 2016-10-16 腫瘤療法 科學股份有限公司 對於ｔｈ１細胞之ｇｐｃ３抗原決定位胜肽及含此之疫苗
CN107619835A (zh) * 2017-05-11 2018-01-23 广东医科大学 Cdca5在胃癌中的表达载体及其构建方法及cdca5在胃癌中特异干扰片段
SG11202000250PA (en) * 2017-07-12 2020-02-27 Nouscom Ag A universal vaccine based on shared tumor neoantigens for prevention and treatment of micro satellite instable (msi) cancers
CN109355394A (zh) * 2018-12-28 2019-02-19 江苏省人民医院（南京医科大学第附属医院） 癌-睾丸抗原cdca5作为食管鳞癌预后标志物及治疗靶点
KR20220012938A (ko) * 2019-05-29 2022-02-04 휴브로 테라퓨틱스 에이에스 펩타이드

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2450067A1 (en) * 2001-06-15 2002-12-27 Incyte Genomics, Inc. Proteins associated with cell growth, differentiation, and death
JP2003135075A (ja) * 2001-11-05 2003-05-13 Research Association For Biotechnology 新規な全長ｃＤＮＡ
CN103951745A (zh) * 2002-09-12 2014-07-30 肿瘤疗法科学股份有限公司 Kdr肽和包括该肽的疫苗
TW201425333A (zh) * 2007-04-11 2014-07-01 Oncotherapy Science Inc 腫瘤血管內皮標誌８胜肽及包含此胜肽之疫苗
JP2010536367A (ja) * 2007-08-24 2010-12-02 オンコセラピー・サイエンス株式会社 癌関連遺伝子、ｃｄｃａ５、ｅｐｈａ７、ｓｔｋ３１及びｗｄｈｄ１
TW200932260A (en) * 2007-11-28 2009-08-01 Oncotherapy Science Inc STAT3 epitope peptides

Also Published As

Publication number Publication date
SG183945A1 (en) 2012-10-30
ZA201207416B (en) 2013-06-26
MX2012011668A (es) 2012-12-17
JP2013523084A (ja) 2013-06-17
CA2795534A1 (en) 2011-10-13
EP2556084A1 (en) 2013-02-13
AU2011236397A1 (en) 2012-11-01
CN102947325B (zh) 2015-04-01
SG10201502791YA (en) 2015-05-28
RU2012147590A (ru) 2014-05-20
KR20130043627A (ko) 2013-04-30
EP2556084A4 (en) 2013-08-14
WO2011125334A1 (en) 2011-10-13
CN102947325A (zh) 2013-02-27
TW201138806A (en) 2011-11-16
US20130108664A1 (en) 2013-05-02

Similar Documents

Publication Publication Date Title
PH12017500484A1 (en) Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers
EA201201306A1 (ru) Новые способы иммунотерапии нескольких видов опухолей, в том числе рака желудочно-кишечного тракта и рака желудка
BR112012025567A2 (pt) peptídeos de cdca5 e vacinas que incluem os mesmos
MX2011008763A (es) Peptidos foxm1 y vacunas que contienen los mismos.
MX350220B (es) Peptidos de mphosph1 y vacunas que incluyen los mismos.
MX2013014489A (es) Peptidos sema5b y vacunas que incluyen los mismos.
BR112012022641A2 (pt) peptídeos hjurp e vacinas que incluem os mesmos
MX342000B (es) Peptidos ect2 y vacunas que los incluyen.
SG10201408245WA (en) Tmem22 peptides and vaccines including the same
MX2020011791A (es) Nuevos peptidos y nueva combinacion de peptidos para el uso en la inmunoterapia contra el carcinoma hepatocelular (chc) y otros tipos de cancer.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.